山河药辅(300452.SZ)公告称，公司原控股股东、实际控制人尹正龙逝世后，其妻吴长虹和女儿尹稚雅 通过继承获得公司股份。本次权益变动后，吴长虹将直接持有山河药辅20.172%股份，尹稚雅直接持有 6.724%股份。同时，吴长虹与尹稚雅签署了《表决权委托协议》，尹稚雅将其所持有山河药辅全部股 份的身份性权利，包括参会权、提名权、提案权、表决权等身份性权利全部委托吴长虹行使。山河药辅 控股股东、实际控制人由尹正龙变更为吴长虹。 ...

证券代码:300452 证券简称:山河药辅 公告编号：2025-051 债券代码:123199 债券简称:山河转债 安徽山河药用辅料股份有限公司 关于大股东签署《表决权委托协议》的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 一、本次表决权委托概述 原实际控制人、控股股东尹正龙先生遗产由其妻子吴长虹、女儿 尹稚雅 两人共同继承，继承后吴长虹女士将直接持有安徽山河药用 辅料股份有限公司（以下简称"公司"） 47,293,091 股股票，占公 司总股本的 20.172%，尹稚雅女士将直接持有公司 15,764,363 股股 票，占公司总股本的 6.724%。为促进公司长期稳定发展，近日，公 司收到尹稚雅女士和吴长虹女士签署的《表决权委托协议》，尹稚雅 女士将其所直接持有的公司股份共计 15,764,363 股表决权委托给 吴长虹女士。协议生效后，吴长虹女士持有的有表决权的股份合计 6 3,057,454 股表决权，约占公司有表决权股份总数的比例为 26.896%。 二、本次签署的《表决权委托协议》的主要内容 （一）甲方自愿将所持全部山河药辅股份的提案权、提名权及投 票权 ...

证券代码:300452 证券简称:山河药辅 公告编号：2025-050 债券代码:123199 债券简称:山河转债 安徽山河药用辅料股份有限公司 关于控股股东、实际控制人发生变更暨股东权益变动的提示 性公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 特别提示： 1、本次权益变动系因公司原控股股东、实际控制人尹正龙先生 逝世后的遗产继承所致，尹正龙先生的配偶吴长虹女士及女儿尹稚雅 女士通过继承的方式获得上市公司股份，不会对公司产生重大不利影 响。 2、本次权益变动后，公司的控股股东、实际控制人由尹正龙先 生变更为吴长虹女士，尹稚雅女士为其一致行动人； 3、本次权益变动不触及要约收购。 安徽山河药用辅料股份有限公司（以下简称"公司"）于近日收 到吴长虹女士、尹稚雅女士出具的《安徽山河药用辅料股份有限公司 详式权益变动报告书》（以下简称"《详式权益变动报告书》"）， 现将相关情况公告如下： 一、本次权益变动基本情况 （一）本次权益变动情况 在本次权益变动前，吴长虹女士、尹稚雅女士未直接或间接持有 公司股份。 2025 年 8 月 26 日，公司原控股股东、实际控制人尹正龙先 ...

住所及通信地址：安徽省淮南市田家庵区XX号 安徽山河药用辅料股份有限公司 详式权益变动报告书 上市公司名称：安徽山河药用辅料股份有限公司 股票上市地点：深圳证券交易所 股票简称：山河药辅 股票代码：300452 信息披露义务人一：吴长虹 信息披露义务人二：尹稚雅 住所及通信地址：安徽省淮南市田家庵区XX号 股份变动性质：继承 签署日期：2025 年 9 月29日 安徽山河药用辅料股份有限公司 详式权益变动报告书 信息披露义务人声明 一、本报告书依据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第15号— —权益变动报告书》等法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书无需获得必要的授权和批准；其履行亦不 违反安徽山河药用辅料股份有限公司章程或内部规则中的任何条款，或与之相冲 突。 三、本报告书已全面披露信息披露义务人在安徽山河药用辅料股份有限公司 中拥有权益的股份变动情况；除本报告书披露的信息外，信息披露义务人没有通 过任何其他方式增加或减少其在安徽山河药用辅料股份有限公司中拥有权益的股 份。 四、本次权益变动是根据本报告所 ...

国元证券股份有限公司 关于安徽山河药用辅料股份有限公司 2025 年半年度持续督导跟踪报告 | 保荐人名称：国元证券股份有限公司 | 被保荐公司简称：山河药辅 | | --- | --- | | 保荐代表人姓名：杨凯强 | 联系电话：0551-62207014 | | 保荐代表人姓名：刘民昊 | 联系电话：0551-62207977 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度 | | | 的情况 | | | （1）是否督导公司建立健全规章制度（包 | | | 括但不限于防止关联方占用公司资源的制 | 是 | | 度、募集资金管理制度、内控制度、内部 | | | 审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 6 次，每月查询公司募集资金专户情况 | | （2）公司募集资金项目进展 ...

Core Viewpoint - Shanhe Pharmaceutical Auxiliary (300452) reported a mixed financial performance for the first half of 2025, with revenue growth but a decline in net profit [1] Financial Performance Summary - Total operating revenue reached 471 million yuan, a year-on-year increase of 4.65% [1] - Net profit attributable to shareholders was 93.03 million yuan, down 2.61% year-on-year [1] - In Q2 2025, operating revenue was 223 million yuan, up 5.06% year-on-year, while net profit was 45.86 million yuan, a slight increase of 0.31% [1] - Gross margin decreased to 32.32%, down 3.4% year-on-year, and net margin fell to 19.8%, down 7.48% year-on-year [1] - Total expenses (selling, administrative, and financial) amounted to 35.03 million yuan, accounting for 7.44% of revenue, a decrease of 1.31% year-on-year [1] - Earnings per share (EPS) was 0.40 yuan, down 2.44% year-on-year, while operating cash flow per share increased significantly by 108.53% to 0.34 yuan [1] Cash Flow Analysis - Net cash flow from operating activities increased by 108.53%, attributed to higher cash receipts from sales and tax refunds [2] - Net cash flow from investing activities decreased by 176.15%, due to increased cash payments for purchasing financial products and construction projects [2] Business Evaluation - The company's return on invested capital (ROIC) was 10.53%, indicating average capital returns, with a historical median ROIC of 14.43% since its listing [2] - The net profit margin for the previous year was 13.66%, suggesting a high added value for products or services [2] - The company has a healthy cash asset position, but attention is needed on accounts receivable, which reached 112.27% of profit [2]

Core Viewpoint - The chairman and actual controller of Shanhe Pharmaceutical Excipients, Yin Zhenglong, passed away at the age of 60, leading to a significant impact on the company's stock price and governance structure [1][3]. Company Overview - Shanhe Pharmaceutical Excipients is engaged in the research, production, and sales of pharmaceutical excipients, with main products including fillers, adhesives, disintegrants, lubricants, and coating materials for oral solid dosage forms and injectable pharmaceutical excipients [2]. Impact of Chairman's Death - Following the announcement of the chairman's death, the company's stock price fell over 4%, closing at 13.64 yuan per share [3]. - The company’s official website has been changed to black and white as a sign of mourning [3]. - Yin Zhenglong was the founder and had served as chairman and general manager since the company's inception, playing a crucial role in its growth and listing on the Shenzhen Stock Exchange [3]. - He held 63,057,454 shares, representing 26.90% of the total shares, making him the controlling shareholder [3]. Governance Transition - The company announced that it will promptly complete the election of a new chairman according to relevant laws and regulations [3]. - In the interim, the current director and general manager, Song Daocai, will assume the responsibilities of chairman and legal representative until a new chairman is elected [3].

Core Viewpoint - The sudden passing of Mr. Yin Zhenglong, the controlling shareholder, actual controller, and chairman of the company, has raised concerns about the future leadership and management of the company [1][3]. Company Overview - Anhui Shanhe Pharmaceutical Excipients Co., Ltd. was established in April 2001 and specializes in the production, research and development, and sales of new pharmaceutical excipients [6]. - The company is a leading player in the domestic pharmaceutical excipients (solid preparations) industry and was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in May 2015 under the stock code 300452 [6]. - The company has a registered capital of 180.46707 million RMB and operates subsidiaries including Qufu Tianli Pharmaceutical Excipients Co., Ltd. (controlling) and Hefei Shanhe Pharmaceutical Technology Co., Ltd. (wholly-owned) [6]. Leadership Transition - Mr. Yin Zhenglong held 63,057,454 shares, accounting for 26.90% of the company's total shares, making him the controlling shareholder and actual controller [3]. - Following Mr. Yin's passing, the company announced that the board of directors would not fall below the legal number of members, ensuring normal operations [3]. - The company’s management team will continue to perform their duties, and the board will expedite the election of a new chairman [3]. - Mr. Song Daocai, a board member and general manager, has been temporarily appointed to fulfill the duties of chairman and legal representative until a new chairman is elected [3].

Core Viewpoint - The passing of Yin Zhenglong, the founder and chairman of Shanhe Pharmaceutical Excipients, marks a significant transition for the company, which has grown from a small local pharmaceutical factory to a leading player in the pharmaceutical excipients industry in China [1][2]. Company Overview - Shanhe Pharmaceutical Excipients was established in April 2001 and specializes in the production, research, and sales of new pharmaceutical excipients, becoming a private joint-stock enterprise [2]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in May 2015 [2]. Leadership Transition - Following the death of Yin Zhenglong on August 26, 2025, the company announced that Song Daocai, the current director and general manager, will temporarily assume the roles of chairman and legal representative until a new chairman is elected [3]. Financial Performance - For the first half of 2025, the company achieved a total operating revenue of 471 million yuan, representing a year-on-year increase of 4.65% [3]. - The net profit attributable to shareholders was approximately 93.04 million yuan, a decrease of 2.61% compared to the previous year [3]. - The net profit after deducting non-recurring gains and losses was about 84.75 million yuan, reflecting a year-on-year growth of 6.05% [3]. Industry Position - Shanhe Pharmaceutical Excipients has positioned itself as a leader in the pharmaceutical excipients sector, with over 170 projects supporting the localization of excipients [2]. - The company offers a wide range of products, including 46 CDE registered products and holds 22 national invention patents, with several core products achieving the highest market share domestically [2].

Core Viewpoint - The passing of Yin Zhenglong, the founder and chairman of Shanhe Pharmaceutical Excipients, is a significant event for the company, which has been under his leadership since its inception. The company is expected to maintain its operations and governance structure despite this loss [4][7][10]. Company Overview - Shanhe Pharmaceutical Excipients was established in April 2001 and specializes in the production, research, and sales of new pharmaceutical excipients. It has become a leading player in the domestic pharmaceutical excipients industry and was listed on the Shenzhen Stock Exchange in May 2015 [10]. - As of August 27, the company's market capitalization was approximately 3.28 billion yuan [10]. Leadership Transition - Yin Zhenglong held 63,057,454 shares, accounting for 26.90% of the total shares, making him the controlling shareholder and actual controller of the company [7]. - Following his passing, the company announced that the board of directors would not fall below the legal number of members, ensuring normal operations. Song Daocai, a current board member and general manager, will temporarily assume the role of chairman until a new chairman is elected [9][10]. Financial Performance - For the first half of 2025, Shanhe Pharmaceutical reported a revenue of 471 million yuan, a year-on-year increase of 4.65%. However, the net profit attributable to shareholders decreased by 2.61% to approximately 93 million yuan [11][12]. - The company’s cash flow from operating activities saw a significant increase of 108.53%, reaching approximately 80 million yuan [12]. - Basic earnings per share decreased by 2.44% to 0.40 yuan, while diluted earnings per share fell by 5.00% to 0.38 yuan [12]. Market Reaction - Following the news of Yin Zhenglong's passing, Shanhe Pharmaceutical's stock price dropped by 2.65%, closing at 13.96 yuan per share on August 27 [13].